Merck: Studies boost Gardasil for new uses - WAOW - Newsline 9, Wausau News, Weather, Sports

Merck: Studies boost Gardasil for new uses

WHITEHOUSE STATION, N.J. (AP) -- New studies show that Merck's Gardasil vaccine appears to protect most young women from cervical cancer and homosexual men from anal cancer.

The vaccine is designed to block four of the most common strains of the sexually transmitted human papilloma virus, or HPV.

Gardasil is already approved for preventing cervical cancer and genital warts in females aged 9 to 26, and for preventing genital warts in males aged 9 to 26.

One of the new studies shows Gardasil appears about 89 percent effective in blocking cervical cancer, genital warts and lingering HPV infections in women aged 24 to 45. The other shows it appears to be 77 percent effective in blocking anal cancer and precancerous lesions in homosexual men.

Merck will seek approval to sell the vaccine for those uses.

(Copyright 2010 by The Associated Press. All Rights Reserved.)

Powered by Frankly